Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer.
Zeligs KP, Morelli MP, David JM, Neuman M, Hernandez L, Hewitt S, Ozaki M, Osei-Tutu A, Anderson D, Andresson T, Das S, Lack J, Abdelmaksoud A, Fantini M, Arlen PM, Tsang KY, Annunziata CM. Zeligs KP, et al. Among authors: annunziata cm. Front Oncol. 2020 Jun 19;10:805. doi: 10.3389/fonc.2020.00805. eCollection 2020. Front Oncol. 2020. PMID: 32637350 Free PMC article.
Driving Immune Responses in the Ovarian Tumor Microenvironment.
Ning F, Cole CB, Annunziata CM. Ning F, et al. Among authors: annunziata cm. Front Oncol. 2021 Jan 15;10:604084. doi: 10.3389/fonc.2020.604084. eCollection 2020. Front Oncol. 2021. PMID: 33520713 Free PMC article. Review.
Editorial: Inhibiting PARP as a Strategic Target in Cancer.
Zorn KK, Annunziata CM. Zorn KK, et al. Among authors: annunziata cm. Front Oncol. 2016 Apr 15;6:91. doi: 10.3389/fonc.2016.00091. eCollection 2016. Front Oncol. 2016. PMID: 27148483 Free PMC article. No abstract available.
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee MJ, Bagheri MH, Botesteanu DA, Steinberg SM, Minasian L, Ekwede I, Kohn EC. Lee JM, et al. Among authors: annunziata cm. Lancet Oncol. 2018 Feb;19(2):207-215. doi: 10.1016/S1470-2045(18)30009-3. Epub 2018 Jan 18. Lancet Oncol. 2018. PMID: 29361470 Free PMC article.
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL. Disis ML, et al. Among authors: annunziata cm. JAMA Oncol. 2019 Mar 1;5(3):393-401. doi: 10.1001/jamaoncol.2018.6258. JAMA Oncol. 2019. PMID: 30676622 Free PMC article. Clinical Trial.
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM. Konstantinopoulos PA, et al. Among authors: annunziata cm. J Clin Oncol. 2020 Apr 10;38(11):1222-1245. doi: 10.1200/JCO.19.02960. Epub 2020 Jan 27. J Clin Oncol. 2020. PMID: 31986064 Free PMC article.
116 results